复旦复华(600624) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders for the first half of 2024 to be between -22.5 million and -15 million yuan, indicating a loss compared to the previous year [2]. - The net profit excluding non-recurring gains and losses is projected to be between -24 million and -16 million yuan for the same period [3]. - In the first half of 2023, the net profit attributable to shareholders was 1.3996 million yuan, with a net profit of -2.723 million yuan after excluding non-recurring gains and losses [4]. Revenue Decline Factors - The decline in revenue and net profit is attributed to the impact of the complex international environment and the depreciation of the Japanese yen against the RMB [5]. - The pharmaceutical subsidiary experienced a decrease in revenue and net profit due to policy changes and price reductions in key products [5]. Financial Reporting - The financial data provided is preliminary and has not been audited by registered accountants, with the final figures to be disclosed in the official half-year report [6].